PURPOSE: We aimed to fulfill a need for a radioligand that may be simply labeled with carbon-11 for effective positron emission tomography (PET) imaging of brain 5-HT(1A) receptors. METHODS: Racemic RWAY (2,3,4,5,6,7-hexahydro-1-[4-[1-[4-(2-methoxyphenyl)piperazinyl]]-2-phenylbutyryl]-1H-azepine) has high affinity for 5-HT(1A) receptors. The enantiomers of RWAY and O-desmethyl-RWAY, synthesized from commercially available materials, were each labeled with carbon-11 by treating the respective O-desmethyl precursor with [(11)C]iodomethane, and injected into rhesus monkey for measurement of regional brain uptake. The 5-HT(1A) selectivity of (R)-[(11)C]RWAY was checked by administering WAY-100635, before and after radioligand administration. Radiometabolites of (R)-[(11)C]RWAY in blood and urine were analyzed by HPLC with partial elucidation of their structures by LC-MS-MS. RESULTS: (R)-[(11)C]RWAY was a 5-HT(1A) receptor antagonist exhibiting high brain uptake with regional distribution consistent with specific binding to 5-HT(1A) receptors. The similar affinity, (S)-[(11)C]RWAY was a weak partial agonist at 5-HT(1A) receptors exhibiting similar brain peak uptake with much less 5-HT(1A) receptor-specific binding. The maximal ratio in receptor-rich cingulate gyrus to receptor-devoid cerebellum reached 6.4 at 87.5 min after injection of (R)-[(11)C]RWAY. After treatment with WAY-100635 before or after (R)-[(11)C]RWAY administration, radioactivity levels in 5-HT(1A) receptor-rich regions were reduced almost to that in cerebellum. Blood and urine radiometabolites were less lipophilic than parent and were not due to hydrolysis but to ring hydroxylations, oxidation, and dephenylation. CONCLUSION: (R)-[(11)C]RWAY is simply prepared and an effective antagonist for imaging brain 5-HT(1A) receptors. This radioligand resists hydrolysis in vivo, gives less lipophilic radiometabolites, and warrants further PET studies in human subjects.
PURPOSE: We aimed to fulfill a need for a radioligand that may be simply labeled with carbon-11 for effective positron emission tomography (PET) imaging of brain 5-HT(1A) receptors. METHODS: Racemic RWAY (2,3,4,5,6,7-hexahydro-1-[4-[1-[4-(2-methoxyphenyl)piperazinyl]]-2-phenylbutyryl]-1H-azepine) has high affinity for 5-HT(1A) receptors. The enantiomers of RWAY and O-desmethyl-RWAY, synthesized from commercially available materials, were each labeled with carbon-11 by treating the respective O-desmethyl precursor with [(11)C]iodomethane, and injected into rhesus monkey for measurement of regional brain uptake. The 5-HT(1A) selectivity of (R)-[(11)C]RWAY was checked by administering WAY-100635, before and after radioligand administration. Radiometabolites of (R)-[(11)C]RWAY in blood and urine were analyzed by HPLC with partial elucidation of their structures by LC-MS-MS. RESULTS: (R)-[(11)C]RWAY was a 5-HT(1A) receptor antagonist exhibiting high brain uptake with regional distribution consistent with specific binding to 5-HT(1A) receptors. The similar affinity, (S)-[(11)C]RWAY was a weak partial agonist at 5-HT(1A) receptors exhibiting similar brain peak uptake with much less 5-HT(1A) receptor-specific binding. The maximal ratio in receptor-rich cingulate gyrus to receptor-devoid cerebellum reached 6.4 at 87.5 min after injection of (R)-[(11)C]RWAY. After treatment with WAY-100635 before or after (R)-[(11)C]RWAY administration, radioactivity levels in 5-HT(1A) receptor-rich regions were reduced almost to that in cerebellum. Blood and urine radiometabolites were less lipophilic than parent and were not due to hydrolysis but to ring hydroxylations, oxidation, and dephenylation. CONCLUSION: (R)-[(11)C]RWAY is simply prepared and an effective antagonist for imaging brain 5-HT(1A) receptors. This radioligand resists hydrolysis in vivo, gives less lipophilic radiometabolites, and warrants further PET studies in human subjects.
Authors: Filip Scheperjans; Nicola Palomero-Gallagher; Christian Grefkes; Axel Schleicher; Karl Zilles Journal: Neuroimage Date: 2005-07-28 Impact factor: 6.556
Authors: V W Pike; C Halldin; J A McCarron; C Lundkvist; E Hirani; H Olsson; S P Hume; P Karlsson; S Osman; C G Swahn; H Hall; H Wikström; M Mensonidas; K G Poole; L Farde Journal: Eur J Nucl Med Date: 1998-04
Authors: S Osman; C Lundkvist; V W Pike; C Halldin; J A McCarron; C G Swahn; N Ginovart; S K Luthra; C J Bench; P M Grasby; H Wikström; T Barf; I A Cliffe; A Fletcher; L Farde Journal: Nucl Med Biol Date: 1996-07 Impact factor: 2.408
Authors: S Osman; C Lundkvist; V W Pike; C Halldin; J A McCarron; C G Swahn; L Farde; N Ginovart; S K Luthra; R N Gunn; C J Bench; P A Sargent; P M Grasby Journal: Nucl Med Biol Date: 1998-04 Impact factor: 2.408
Authors: Richard E Carson; Yanjun Wu; Lixin Lang; Ying Ma; Margaret G Der; Peter Herscovitch; William C Eckelman Journal: J Cereb Blood Flow Metab Date: 2003-02 Impact factor: 6.200
Authors: Saurav Shrestha; Jussi Hirvonen; Christina S Hines; Ioline D Henter; Per Svenningsson; Victor W Pike; Robert B Innis Journal: Neuroimage Date: 2011-11-25 Impact factor: 6.556
Authors: Stal Saurav Shrestha; Eric E Nelson; Jeih-San Liow; Robert Gladding; Chul Hyoung Lyoo; Pam L Noble; Cheryl Morse; Ioline D Henter; Jeremy Kruger; Bo Zhang; Stephen J Suomi; Per Svenningsson; Victor W Pike; James T Winslow; Ellen Leibenluft; Daniel S Pine; Robert B Innis Journal: Am J Psychiatry Date: 2014-03 Impact factor: 18.112
Authors: Sami S Zoghbi; Kacey B Anderson; Kimberly J Jenko; David A Luckenbaugh; Robert B Innis; Victor W Pike Journal: J Pharm Sci Date: 2011-12-13 Impact factor: 3.534
Authors: Louise M Paterson; Birgitte R Kornum; David J Nutt; Victor W Pike; Gitte M Knudsen Journal: Med Res Rev Date: 2011-06-14 Impact factor: 12.944